Journal Article

DZNE-2025-00031

http://join2-wiki.gsi.de/foswiki/pub/Main/Artwork/join2_logo100x88.png Prognostic serum biomarkers of synaptic, neuronal and glial injury in patients with acute ischemic stroke of the anterior circulation.

Barba, L. ; Vollmuth, C. ; Halbgebauer, S.DZNE* ; Ungethüm, K. ; Hametner, C. ; Essig, F. ; Kollikowski, A. M. ; Pham, M. ; Schuhmann, M. K. ; Heuschmann, P. U. ; Oeckl, P.DZNE* ; Steinacker, P. ; Romoli, M. ; D'Anna, L. ; Abu-Rumeileh, S. ; Haeusler, K. G. ; Stoll, G. ; Neugebauer, H. ; Otto, M.

2025
Wiley-Blackwell Oxford [u.a.]

This record in other databases:    

Please use a persistent id in citations: doi:10.1111/ene.16581

Abstract: We aimed to investigate the prognostic role of β-synuclein in comparison to that of neurofilament light chain (NfL) and glial fibrillary acidic protein (GFAP) for predicting functional outcome after acute ischemic stroke (AIS).We measured serum concentrations of β-synuclein, NfL and GFAP 24 h after hospital admission in 213 consecutive patients with moderate-to-severe AIS. We investigated the association between serum biomarkers and radiological/clinical characteristics, 3-months mortality and functional outcome on the modified Rankin Scale (mRS).In 213 patients with AIS [mean age: 76.1 (±12.5) years, 53.1% males, median NIHSS score on admission: 13 (IQR: 9-17)], higher levels of β-synuclein, NfL and GFAP were associated with higher NIHSS scores and with lower Alberta Stroke Program CT Score (ASPECTS) points on admission. Serum β-synuclein levels was significantly correlated with NfL (rho = 0.715, p < 0.001) and GFAP concentrations (rho = 0.684, p < 0.001). The inclusion of serum β-synuclein significantly improved the accuracy of prediction models without biomarkers for overall mortality (AUC: 0.836 vs. 0.752, p < 0.001) and mRS 3-6 vs. 0-2 (AUC: 0.812 vs. 0.624, p < 0.001). Combination models with NfL and/or GFAP showed a similar accuracy.Serum β-synuclein may be used to assess synaptic damage/dysfunction and to predict 3-months clinical outcomes in patients with AIS.

Keyword(s): Humans (MeSH) ; Male (MeSH) ; Female (MeSH) ; Aged (MeSH) ; Biomarkers: blood (MeSH) ; Ischemic Stroke: blood (MeSH) ; Ischemic Stroke: mortality (MeSH) ; Prognosis (MeSH) ; Aged, 80 and over (MeSH) ; Glial Fibrillary Acidic Protein: blood (MeSH) ; Neurofilament Proteins: blood (MeSH) ; Middle Aged (MeSH) ; Neuroglia (MeSH) ; Neurons: pathology (MeSH) ; Synapses (MeSH) ; GFAP ; NfL ; beta‐synuclein ; biomarkers ; stroke ; Biomarkers ; Glial Fibrillary Acidic Protein ; neurofilament protein L ; Neurofilament Proteins ; GFAP protein, human

---

Contributing Institute(s):

1. Clinical Study Center (Ulm) (Clinical Study Center (Ulm))
2. Translational Mass Spectrometry and Biomarker Research (AG Öckl)

Research Program(s):

1. 353 - Clinical and Health Care Research (POF4-353) (POF4-353)

Appears in the scientific report 2025

---

Database coverage:
; ; ; BIOSIS Previews ; Biological Abstracts ; Clarivate Analytics Master Journal List ; Current Contents - Clinical Medicine ; DEAL Wiley ; Ebsco Academic Search ; Essential Science Indicators ; IF >= 5 ; JCR ; SCOPUS ; Science Citation Index Expanded ; Web of Science Core Collection

---